概括
在分娩过程中服用一次尼维拉平的剂量可以在7天内保护新生儿免受HIV-1感染. 然而,孕妇在怀孕期间使用尼维拉会导致新生儿的药物清除速度更快,这表明在子宫内诱导肝酶.
科学领域:
- 药理学 药理学是指药理学的学科.
- 新生儿健康 新生儿健康
- 预防传染病 预防传染病
背景情况:
- 尼维拉平用于预防人类免疫缺陷病毒1型 (HIV-1) 的母婴传播.
- 一次性产科内尼维拉剂可为新生儿提供短期保护,防止艾滋病毒-1感染.
- 之前的观察表明,基于母亲治疗时间,内维拉平的药理动力学可能存在差异.
研究的目的:
- 为了研究内维拉在新生儿中的药理动力学概况,在怀孕期间与分娩期间进行母亲治疗后.
- 评估内宫内暴露于内维拉平对新生儿内维拉平消除的影响.
- 了解新生儿内维拉平度改变对HIV-1预防策略的影响.
主要方法:
- 新生儿血内维拉平度的药理动力学分析.
- 在新生儿中药物清除率的比较,这些新生儿在子宫内暴露于尼维拉,而不是仅在分娩期间.
- 鉴于母体内维拉平的使用,对胎儿潜在的肝酶诱导的评估.
主要成果:
- 新生儿血中的内维拉平度在母亲在怀孕期间接受了内维拉平治疗的婴儿中下降的速度更快.
- 这种加速下降表明代谢活动增加,可能是由于妊娠期间肝酶诱导.
- 单次产后剂量提供了长达7天的保护,但有效药物水平的持续时间可能在先前的孕产妇暴露时更短.
结论:
- 孕妇在怀孕期间接受尼维拉平治疗会诱导胎儿的肝酶,导致新生儿的尼维拉平清除更快.
- 这一发现对优化nevirapine剂量策略对婴儿HIV-1预防有意义.
- 需要进一步的研究来确定尼维拉平预防的最佳时间和持续时间,以确保对垂直HIV-1传播的充分保护.
相关概念视频
Drug Distribution: Tissue Binding
Upon entering the systemic circulation, drugs can distribute into the interstitial and intracellular fluid of various tissue cells. This distribution is facilitated by the binding of drugs to different cellular components within tissues, which may lead to drug accumulation in specific areas. Drugs bound to tissue components serve as reservoirs that release free drugs back into the system, prolonging the drug's overall action. However, this accumulation can also result in local toxicity.
For...
For...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Pharmacokinetics in Pediatric Patients: Drug Distribution
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Pharmacokinetics in Pediatric Patients: Drug Metabolism
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Drug Toxicity: Dose-Dependent Reactions
Drug toxicities can be stratified into pharmacological, pathological, or genotoxic based on their mechanisms. The incidence and severity of these toxicities generally increase with the drug's concentration in the body and exposure time.Pharmacological toxicity is evident when the therapeutic effects of drugs overshoot into adverse reactions in a predictable, dose-dependent manner. Central nervous system (CNS) depression from barbiturates is a classic example, with effects escalating from...


